Prognostic Role of Squamous Cell Carcinoma Antigen in Cervical Cancer: A Meta-analysis

Abstract

Objective. To systematically evaluate the significance of squamous cell carcinoma antigen (SCC-Ag) in the prognosis of cervical cancer. Methods. Literature from Pubmed, Embase, and Cochrane Library was retrieved to collect all English literature on the correlation between SCC-Ag and cervical cancer prognosis, and the quality of literature collected was assessed based on evaluation criteria. The heterogeneity, sensitivity, and specificity were detected using the StataSE12.0 software, and the correlation between SCC-Ag and cervical cancer prognosis as the effect variables was assessed using the hazard ratio (HR) and 95% confidence interval (CI). Moreover, the forest map and funnel plot were drawn. Results. A total of 17 articles meeting the inclusion criteria were selected. The high expression of SCC-Ag was significantly correlated with the poor prognosis of cervical cancer (HR=2.22, 95% CI=1.38−3.57, P=0.002). The disease-free survival (DFS) was higher in low SCC-Ag expression patients than in high SCC-Ag expression patients (HR=2.17, 95% CI=1.84−2.57, P<0.001). The progression-free survival (PFS) was inferior in patients with a high SCC-Ag expression (HR=2.70, 95% CI=1.11−6.53, P=0.028). Conclusion. SCC-Ag is an important prognostic factor for cervical cancer, and its high expression is significantly correlated with a poor prognosis of the disease.

Detection of Recurrent Cervical Cancer and Prediction of Its Patient Survival with Serum Squamous-Cell Carcinoma-Antigen and 2-[18F] Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography

“…Meanwhile, the OS and DFS were significantly lower in patients with elevated SCC-Ag levels than in those without (p < 0.001 and p < 0.001, respectively), indicating that patients with elevated SCC-Ag levels have a low survival rate. The prognostic role of SCC-Ag in recurrent cervical cancer is consistent with the meta-analysis results of a recently published article [32].…”

“…Zhou et al conducted a retrospective review of 17 studies with 707 patients who underwent FDG-PET/CT scans for the detection of the recurrence of cervical cancer; the sensitivity and specificity of FDG-PET/CT were 97% (range, 95-99%) and 81% (range, 74-87%), respectively. In contrast, the sensitivity and specificity owing to elevated serum SCC-Ag levels were 99% (range, 93-100%) and 77% (range, 59-89%), respectively [32]. They suggested that FDG-PET/CT is a more suitable option for detecting suspected cases of recurrent cervical cancer, especially in patients who have elevated serum SCC-Ag levels.…”

Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients

“…Serum biomarkers, holding the potential of cost-effectiveness, non-invasivity, and reproducibility, are often used in clinical practice for early tumor detection, response to treatment monitoring and prognosis prediction ( 5 ). Several biomarkers with potential prognostic role have been identified in UCC ( 6 , 7 ), but none of them has been introduced in clinical practice so far. Among recently reported serum biomarkers in gynecological cancer, one of the most promising is the Human Epididymis Protein 4 (HE4 or WFDC2), a member of the whey acidic protein (WAP) four-disulfide core gene cluster bearing a conserved motif found in several protease inhibitors ( 8 ).…”

Single-Sample Node Entropy for Molecular Transition in Pre-deterioration Stage of Cancer

“…Cancer has become the most difficult disease in all medical fields and is one of the leading causes of death in the world (Nordin et al, 2019). Unfortunately, cancer progression can be inconspicuously with non-typical clinical symptoms (Yang et al, 2018;Liu and Shi, 2019). When most patients have pathological symptoms that can be easily diagnosed clinically, they may have already reached the advanced stage (Miller et al, 2019).…”